Cell Therapy Contract Development and Manufacturing Organization Market Size & Share Analysis - Growth, Trends and Forecasts (2024 - 2029)

Cell Therapy Contract Development And Manufacturing Organization Market Analysis

The Cell Therapy Contract Development And Manufacturing Organization Market size is estimated at USD 1.63 billion in 2024, and is expected to reach USD 6.40 billion by 2029, growing at a CAGR of 25.70% during the forecast period (2024-2029).

The major factors boosting the growth of the cell therapy market are the rise in preclinical and clinical activities around cell therapy, the increasing burden of chronic diseases, and high investment in cell therapy development. The growing disease burden, characterized by diverse health challenges ranging from chronic diseases to infectious threats, drives significant demand for cell therapy contract development and manufacturing services. For instance, as stated in the British Heart Foundation England Factsheet released in January 2024, about 7.6 million people live with cardiovascular diseases in England in 2022. As per the same source, around 620 million people had heart and circulatory diseases (cardiovascular diseases) across the world in 2022. Cell therapies targeting cells associated with chronic conditions. Hence, the growing chronic disease burden is poised to drive market expansion during the forecast period.

The growth of preclinical and clinical activities in cell therapy creates increased demand for CDMO. These specialized service providers offer expertise in process development, manufacturing, and regulatory compliance, supporting the progression of cell therapies from research to commercialization. As the cell therapy market expands, CDMOs play a pivotal role in accelerating product development, ensuring quality, and navigating regulatory complexities, thereby boosting the overall demand for cell therapy CDMO services. For instance, in September 2023, C3i provided process development and manufacturing to Phase III with the expected goal of commercial launch at the end of 2024. C3i Center Inc. announced the manufacturing of a cell therapy product for Europe that is currently in Phase II clinical trials.

Further, growing collaboration and partnerships between biopharmaceutical companies and CDMOs are anticipated to provide an opportunity for market players in the growth of the cell and gene therapy CDMO services market during the forecast period. For instance, in October 2023, eXmoor Pharma launched its new Cell and Gene Therapy Centre good manufacturing practice (GMP) facility to support the production of multiple therapies for clinical trials. Similarly, in June 2023, Quell Therapeutics and AstraZeneca signed a licensing deal to develop, manufacture, and commercialize engineered Treg cell therapies for autoimmune disorders.

Hence, increasing preclinical and clinical trial activities around cell therapy and market players' strategic activities, such as mergers and acquisitions, are expected to boost the market during the forecast period. However, the high cost of researching complex manufacturing processes and regulatory challenges hamper market growth.

Cell Therapy Contract Development And Manufacturing Organization Market Trends

The Oncology Segment is Expected to Hold a Significant Share During the Forecast Period

Cell Therapy Contract Development And Manufacturing Organization Industry Segmentation

As per the scope of the report, cell therapy CDMO services refer to specialized offerings provided by companies that support the development, production, and testing of cell therapies. The cell therapy contract development and manufacturing organization market is segmented by services, source, indication, phase, end users, and geography. Services segment the market as stem-cell-based, non-stem-cell-based, and other therapies. By source, the market is segmented as clinical and commercial. The market is segmented by indications such as oncology, cardiovascular disease, infectious disease, genetic disorders, neurological disorders, and other indications. The market is segmented by Phase (Phase I, Phase II, Phase III, and Phase IV). The market is segmented by end users as pharmaceutical & biotechnology, companies, academics & research institutes. The market is segmented by geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for the above segments.